These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Nikkilä EA; Ylikahri R; Huttunen JK Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608 [TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Hollenbeck CB; Johnston P; Varasteh BB; Chen YD; Reaven GM Diabete Metab; 1991; 17(5):483-9. PubMed ID: 1752350 [TBL] [Abstract][Full Text] [Related]
4. The influence of plasma triglycerides on human growth hormone response to arginine and insulin: a study in hyperlipemics and normal subjects. Muggeo M; Tiengo A; Fedele D; Crepaldi G Horm Metab Res; 1975 Sep; 7(5):367-74. PubMed ID: 1183914 [TBL] [Abstract][Full Text] [Related]
5. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Koopmans SJ; Mroz Z; Dekker R; Corbijn H; Ackermans M; Sauerwein H Metabolism; 2006 Jul; 55(7):960-71. PubMed ID: 16784971 [TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093 [TBL] [Abstract][Full Text] [Related]
7. Short-term effects of metformin in type 2 diabetes. Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA Diabetes Obes Metab; 2007 Jul; 9(4):483-9. PubMed ID: 17587390 [TBL] [Abstract][Full Text] [Related]
9. Short-term effects of metformin in type 2 diabetes. Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA Diabetes Obes Metab; 2007 May; 9(3):330-6. PubMed ID: 17391159 [TBL] [Abstract][Full Text] [Related]
10. Lipid, glucose, and insulin interrelationships in normal, prediabetic, and chemical diabetic subjects. Kyner JL; Levy RI; Soeldner JS; Gleason RE; Fredrickson DS J Lab Clin Med; 1976 Sep; 88(3):345-58. PubMed ID: 956689 [TBL] [Abstract][Full Text] [Related]
11. Metformin in the treatment of obesity in subjects with normal glucose tolerance. Tankova T; Dakovska L; Kirilov G; Koev D Rom J Intern Med; 2003; 41(3):269-75. PubMed ID: 15526510 [TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368 [TBL] [Abstract][Full Text] [Related]
14. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Noury J; Nandeuil A Diabete Metab; 1991 May; 17(1 Pt 2):209-12. PubMed ID: 1936478 [TBL] [Abstract][Full Text] [Related]
15. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194 [TBL] [Abstract][Full Text] [Related]
16. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Chazova I; Almazov VA; Shlyakhto E Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753 [TBL] [Abstract][Full Text] [Related]
17. Anti-diabetic property of ethanolic extract of Andrographis paniculata in streptozotocin-diabetic rats. Zhang XF; Tan BK Acta Pharmacol Sin; 2000 Dec; 21(12):1157-64. PubMed ID: 11603293 [TBL] [Abstract][Full Text] [Related]
18. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Vague P; Juhan-Vague I; Alessi MC; Badier C; Valadier J Thromb Haemost; 1987 Jun; 57(3):326-8. PubMed ID: 3310318 [TBL] [Abstract][Full Text] [Related]
19. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. Yasuda N; Inoue T; Nagakura T; Yamazaki K; Kira K; Saeki T; Tanaka I J Pharmacol Exp Ther; 2004 Aug; 310(2):614-9. PubMed ID: 15039452 [TBL] [Abstract][Full Text] [Related]
20. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM). Elkeles RS Diabete Metab; 1991 May; 17(1 Pt 2):197-200. PubMed ID: 1936476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]